Ryan Carpentier Discusses CAR T Therapy Successes and Challenges in Contract Pharma

September 10, 2019

In a new article for Contract Pharma, Cryoport Executive Director of Business Development Ryan Carpentier explains the exciting new opportunities of CAR T-cell immunotherapy, which enables a patient’s immune system to recognize and destroy cancer cells.

Cryoport supports the Novartis therapy Kymriah, one of two FDA-approved CAR T-cell therapies.  

Read the full article 

More Cryoport News 

Tags: Temperature Controlled Logistics, cold chain shipping, transportation, Cryoport News, Biopharma Industry News